Karriereverlauf von Ira Wallis
Ehemalige bekannte Positionen von Ira Wallis
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
Tercica, Inc.
 Tercica, Inc. Pharmaceuticals: MajorHealth Technology The Company's principal activity as a biopharmaceutical company is focused on the development and commercialization of products to improve endocrine health. Its first product, IncrelexTM (mecasermin {rDNA origin} injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved by the FDA for the treatment of severe Primary IGFD. The Company licensed the rights to develop, manufacture and commercialize Increlex from Genentech Inc. | General Counsel | - | 03.02.2014 |
| DYNAVAX TECHNOLOGIES CORPORATION | General Counsel | 01.05.2001 | 01.01.2003 |
| CERUS CORPORATION | Direktor/Vorstandsmitglied | 01.07.1996 | 01.04.2001 |
| General Counsel | 01.07.1996 | 01.04.2001 | |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | General Counsel | 01.01.1990 | 01.01.1996 |
| Sandoz Pharmaceuticals Corp. | General Counsel | 01.01.1987 | 01.01.1989 |
Ausbildung von Ira Wallis
| American International College | Undergraduate Degree |
| State University of New York at Buffalo | Doctorate Degree |
Statistik
International
| Vereinigte Staaten | 8 |
Operativ
| General Counsel | 5 |
| Director/Board Member | 1 |
| Undergraduate Degree | 1 |
Sektoral
| Health Technology | 5 |
| Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| DYNAVAX TECHNOLOGIES CORPORATION | Health Technology |
| CERUS CORPORATION | Health Technology |
| Private Unternehmen | 3 |
|---|---|
Tercica, Inc.
Tercica, Inc. Pharmaceuticals: MajorHealth Technology The Company's principal activity as a biopharmaceutical company is focused on the development and commercialization of products to improve endocrine health. Its first product, IncrelexTM (mecasermin {rDNA origin} injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved by the FDA for the treatment of severe Primary IGFD. The Company licensed the rights to develop, manufacture and commercialize Increlex from Genentech Inc. | Health Technology |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
| Sandoz Pharmaceuticals Corp. |
- Börse
- Insiders
- Ira Wallis
- Erfahrung